Analysis of persistence and health care costs in the us medicaid population opioid-dependent patients treated with buprenorphine / naloxone film and tablet formulations

Analysis of persistence and health care costs in the us medicaid population opioid-dependent patients treated with buprenorphine / naloxone film and tablet formulations

2013 Value in health

Kharitonova, E. | Aballea, S. | Clay, E. | Ruby, J. | Zah, V. | Volume: 16, Issue: 3, Pages: A58-A59, analysis, Health Care Costs, opioid dependence, database,

Buprenorphine/naloxone combination (BUP/NAL) has been available in a film formulation since 2010 for the treatment of opioid dependence. A clinical trial showed that patients preferred the film to tablet formulation. Insurance claims data extracted from MarketScan Medicaid database were analyzed to compare patient persistence and health care costs between the two formulations.